YP-01001

N/A

Report date: 2022/12/09 14:30:50
NME

Base Information

Drug NameYP-01001
Drug Alias NameYP-01001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsFibroblast growth factor receptors antagonistsTyrosine-protein kinase receptor RET inhibitors
TargetsVascular endothelial growth factor receptorFibroblast growth factor receptorsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsSolid tumoursThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYaopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYaopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursThyroid Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A